Spend $79 more and get free shipping!
Your cart is empty
Mounjaro contains the active ingredient tirzepatide, a GLP-1 and GIP receptor agonist. It behaves like the natural hormones GLP-1 and GIP to lower blood glucose concentrations, slow gastric emptying, regulate appetite and decrease food intake.
Mounjaro is a prescription medicine, and requires a prescription from a New Zealand registered healthcare professional.
The starting dose of Mounjaro is 2.5 mg once weekly. After 4 weeks, a prescribing healthcare professional may increase the dose to 5 mg once weekly, the first maintenance dose. Subsequent dose increases are to be determined by a prescribing healthcare professional.
Mounjaro contains a long-acting receptor agonist that targets GIP and GLP-1 receptors throughout the body.
Mounjaro is approved for adults who are living with:
Mounjaro is a prescription medicine. Your doctor will review your health status and eligibility as part of an assessment.
Additional care:
If you experience slowing down or blockage of your intestinal function, tell your doctor as soon as possible.
Managing side effects
This information is for educational purposes only. Always consult with your healthcare provider before starting any new medication.
TAPS Approval No: PP4508